GT Biopharma
GTBP
40 hedge funds and large institutions have $70.1M invested in GT Biopharma in 2021 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
6,938% more capital inflows, than outflows
Capital inflows: $55.8M | Capital outflows: $793K
625% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 4
167% more funds holding
Funds holding: 15 → 40 (+25)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
18.66% more ownership
Funds ownership: 2.73% → 21.39% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.19M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$291K |
| 2 |
Millennium Management
New York
|
-$191K |
| 3 |
Virtu Financial
New York
|
-$156K |
| 4 |
Squarepoint
New York
|
-$113K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$20.8K |
GTBP Hedge Fund Activity: Q2 2021 in Review
40 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2021, worth a combined $70.1M — up 1,662% from $3.98M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new GTBP positions and 4 closed out — a net gain of 25 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $19.6M. The largest seller was Royal Bank of Canada, cutting an estimated $291K.
- 40 institutional investors held GT Biopharma (GTBP) as of Q2 2021, up from 15 in Q1 2021.
- Funds reported $70.1M of GT Biopharma stock for Q2 2021, up 1,662% quarter-over-quarter.
- 29 funds opened new GT Biopharma positions in Q2 2021 and 4 closed out, a net change of +25 holders.
- The largest GT Biopharma buyer in Q2 2021 was BlackRock, an estimated $19.6M added.
- The largest GT Biopharma seller in Q2 2021 was Royal Bank of Canada, an estimated $291K sold.
Based on aggregated 13F filings for Q2 2021.